新型生长因子组合促进肩袖修复:大鼠体内研究
该研究在大鼠肩袖修复模型中,将转化生长因子β1、胰岛素样生长因子1和甲状旁腺激素组合通过PVA-酪胺凝胶递送至腱骨界面,发现该组合在体外促进人腱细胞增殖和腱、软骨、骨相关基因表达,在体内6周和12周时组织学愈合质量和生物力学性能均优于对照组,但结论需进一步研究验证。
要点
- 体外实验中,生长因子组合使人腱细胞增殖为对照组的1.5倍(P=0.04)。
- 体内大鼠模型中,生长因子组在6周和12周时的失效载荷和杨氏模量均高于对照组1.5倍以上。
- 作者认为该生长因子组合可转化为临床并可能改善肩袖修复后的愈合。
核心结论
- 生长因子组合在体外促进人腱细胞的腱性和软骨性反应,并在体内改善修复的组织学表现和力学性能。
- 腱骨界面的微阵列分析发现生长因子组合影响炎症和矿化通路,为进一步研究提供新治疗靶点。
研究设计与样本
- 控制性实验室研究:体外培养人腱细胞72小时,体内采用46只成年大鼠左侧冈上肌腱离断修复模型。
- 使用PVA-酪胺凝胶将生长因子组合递送至腱骨界面,术后6周和12周进行组织学、生物力学和RNA微阵列分析,12周进行II型和X型胶原免疫组化。
主要发现
- 体外实验中,生长因子组合组人腱细胞增殖为对照组的1.5倍(P=0.04),scleraxis表达增加65倍(P=0.013),Sox-9(P=0.011)、I型胶原(P=0.021)、纤维调节蛋白(P=0.0075)和双糖链蛋白聚糖(P=0.010)表达显著增加,PPARγ表达降低(P=0.007)。
- 术后6周和12周,生长因子组组织学愈合质量显著高于对照组,形成更成熟的腱骨界面,经II型和X型胶原免疫组化确认。
- 生长因子组在6周和12周时的失效载荷和杨氏模量均高于对照组1.5倍以上。
- 6周微阵列显示生长因子组上调白细胞聚集相关基因(S100A8、S100A9)和组织矿化相关基因(Bglap、serglycin、Fam20c)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The lack of healing at the repaired tendon-bone interface is an important cause of failure after rotator cuff repair. While augmentation with growth factors (GFs) has demonstrated promise, the ideal combination must target all 3 tissue types at the tendon-bone interface. HYPOTHESIS: The GF combination of transforming growth factor beta 1, Insulin-like growth factor 1, and parathyroid hormone will promote tenocyte proliferation and differentiation and improve the biomechanical and histological quality of the repaired tendon-bone interface. STUDY DESIGN: Controlled laboratory study. METHODS: In vitro, human tenocytes were cultured in the presence of the GF combination for 72 hours, and cell growth assays and the expression of genes specific to tendon, cartilage, and bone were analyzed. In vivo, adult rats (N = 46) underwent detachment and repair of the left supraspinatus tendon. A PVA-tyramine gel was used to deliver the GF combination to the tendon-bone interface. Histological, biomechanical, and RNA microarray analysis was performed at 6 and 12 weeks after surgery. Immunohistochemistry for type II and X collagen was performed at 12 weeks. RESULTS: When treated with the GF combination in vitro, human tenocytes proliferated 1.5 times more than control (P = .04). The expression of scleraxis increased 65-fold (P = .013). The expression of Sox-9 (P = .011), type I collagen (P = .021), fibromodulin (P = .0075), and biglycan (P = .010) was also significantly increased, while the expression of PPARγ was decreased (P = .007). At 6 and 12 weeks postoperatively, the quality of healing on histology was significantly higher in the GF group, with the formation of a more mature tendon-bone interface, as confirmed by immunohistochemistry for type II and X collagen. The GF group achieved a load at failure and Young modulus >1.5 times higher at both time points. Microarrays at 6 weeks demonstrated upregulation of genes involved in leukocyte aggregation (S100A8, S100A9) and tissue mineralization (Bglap, serglycin, Fam20c). CONCLUSION: The GF combination promoted protendon and cartilage responses in human tenocytes in vitro; it also improved the histological appearance and mechanical properties of the repair in vivo. Microarrays of the tendon-bone interface identified inflammatory and mineralization pathways affected by the GF combination, providing novel therapeutic targets for further research. CLINICAL RELEVANCE: The use of this GF combination is translatable to patients and may improve healing after rotator cuff repair.
引用
- Zhu M, Lin Tay M, Lim KS, et al. Novel Growth Factor Combination for Improving Rotator Cuff Repair: A Rat In Vivo Study. Am J Sports Med. 2022. PMID: 35188803. doi:10.1177/03635465211072557
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。